Humankind Investments LLC Makes New $216,000 Investment in DaVita Inc. $DVA

Humankind Investments LLC bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 1,412 shares of the company’s stock, valued at approximately $216,000.

Several other institutional investors also recently made changes to their positions in the stock. Banco Bilbao Vizcaya Argentaria S.A. boosted its position in shares of DaVita by 3.6% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 17,956 shares of the company’s stock worth $2,747,000 after buying an additional 626 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of DaVita by 207.9% in the 1st quarter. Wellington Management Group LLP now owns 8,348 shares of the company’s stock worth $1,277,000 after buying an additional 5,637 shares in the last quarter. Northern Trust Corp boosted its position in shares of DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares in the last quarter. Versor Investments LP purchased a new stake in shares of DaVita in the 1st quarter worth about $244,000. Finally, Raymond James Financial Inc. boosted its position in shares of DaVita by 6.8% in the 1st quarter. Raymond James Financial Inc. now owns 27,604 shares of the company’s stock worth $4,223,000 after buying an additional 1,768 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Up 0.6%

Shares of DVA stock opened at $137.4890 on Thursday. The firm has a 50-day moving average price of $139.54 and a 200 day moving average price of $144.65. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The company has a market capitalization of $9.83 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 0.98 and a beta of 1.09. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter in the prior year, the company posted $2.00 EPS. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Activity

In other news, insider James O. Hearty sold 2,351 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of several recent research reports. Truist Financial set a $148.00 price objective on shares of DaVita in a research report on Friday, August 8th. Barclays cut their target price on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $164.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.